Hemoglobin >=  g/dL, patients may receive transfusion to meet criterion within  days of day  of study
Total hemoglobin >=  g/dL (may be post-transfusion)
Hemoglobin >  g/dL, transfusion permitted
Pre-transfusion hemoglobin of <=  g/dL,
Hemoglobin >=  gm/dL (transfusion is allowed to reach minimum level)
Total hemoglobin >=  g/dL (which may be post transfusion)
Hemoglobin >= . g/dL (may be supported by erythropoietin) AND
Hemoglobin ? mg/dL (transfusion to reach this level is permitted)
Hemoglobin ?. g/dL without transfusion within the  weeks prior to Day .
Hemoglobin >= . g/dl (without transfusion within the previous  days)
Hemoglobin >= . gm/dL; transfusion permitted to achieve this level
Hemoglobin <  g/dL (hemoglobin may be supported by transfusion, erythropoietin, or other approved hematopoietic growth factors)
hemoglobin ?  g/dL; subjects requiring transfusion will be eligible to start study
Hemoglobin >= . g/dL (may be supported by erythropoietin)
Hemoglobin >=  gm/dL (transfusion is allowed to reach minimum level)
Hemoglobin >=  g/dl (may achieve by transfusion)
Hemoglobin >=  g/dL without transfusion within  days prior to enrollment
Hemoglobin >=  g/dL with no blood transfusion in the past  days, =<  days prior to CD
Hemoglobin >=  g/dL (transfusion to meet eligibility allowed)
Within  days of enrollment and with  h of starting lymphodepleting chemotherapy: Hemoglobin >= . g/dL (transfusion allowed).
Hemoglobin >= . g/dl, with or without transfusion
Hemoglobin  g/dl or more; (transfusion permitted)
Hemoglobin  g/dl or more; (transfusion permitted)
Hemoglobin >= . g/dL independent of transfusion.
Hemoglobin >=  g/dL but transfusion allowed
Hemoglobin >= g/dL (transfusion permitted)
REP ELIGIBILITY: Hemoglobin greater than or equal to . g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is  gm/dL)
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Hemoglobin greater than or equal to . g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is  gm/dL)
Hemoglobin >  g/dL, without transfusion or hematopoietic growth factor
Hemoglobin >= . g/dL with no blood transfusion within  days of starting treatment
Participants with hemoglobin level >=  g/dL, within  days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
Participants with hemoglobin level <  g/dL, within  days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
Hemoglobin >=  (with or without transfusion)
Hemoglobin >= . g/dL (transfusion is allowed to correct anemia).
Hemoglobin >=  mg/dL (Note: Transfusion may be used for eligibility outside of  days)
Hemoglobin (no transfusion within prior  days) >= . g/dL
Hemoglobin >=  g/dL (transfusion allowed but must demonstrate stability after transfusion)
Hemoglobin >=  g/dL (no blood transfusion in the  days prior to entry [olaparib guidelines])
Hemoglobin >=  g/dL (transfusion to obtain hemoglobin >=  g/dL within  hours prior to dosing is allowed)
Hemoglobin < . g/dL (transfusion permitted at least  days prior to baseline)
Hemoglobin >= . g/dL (transfusion permitted)
Hemoglobin >=  g/dL\r\n* May receive transfusion to meet this goal
Hemoglobin >=  g/dL\r\n* Note: Patients requiring transfusion to meet the hemoglobin requirement are not eligible for the study
PHASE I: Hemoglobin >=  g/dl, and no blood transfusion within  weeks; OR >  g/dL, and no blood transfusion within  weeks
PHASE II SCLC: Hemoglobin >=  g/dl, and no blood transfusion within  weeks; OR >  g/dL, and no blood transfusion within  weeks
Hemoglobin > . g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)
Hemoglobin ? . g/dL (in the absence of transfusion within  weeks before randomization)
Hemoglobin >= . g/dL, which must be stable in the opinion of the investigator without a history of transfusion dependence
Hemoglobin >=  g/dL without transfusion dependency
Hemoglobin >=  g/dL without transfusion within  days prior to enrollment
Hemoglobin >=  g/dL qualifications (transfusion permitted)
Hemoglobin >= . g/dL with last transfusion at least  days before day  of study drug
Hemoglobin greater than . g/dL (transfusion independent; no transfusion for >=  days prior to study enrollment)
Hemoglobin  gl/dl (transfusion allowed)
Hemoglobin >=  g/dL (may be post-transfusion)
Hemoglobin >= . mg/dL without transfusion in  prior weeks
Hemoglobin < g/dL (may receive transfusion or erythropoietin to maintain)
Hemoglobin >= . g/dL without transfusion if stem cells are not available
Hemoglobin >=  g/dL (transfusion permitted)
Hemoglobin >= . g/dL (after transfusion if required)
Hemoglobin >=  g/dL; continuation of erythropoietin products is permitted; hemoglobin must be stable above  g/dL for at least  weeks without blood transfusion to maintain hemoglobin level
Hemoglobin >  gm/dL without transfusion and off erythropoietin for  days or darbepoetin (Aranesp) for  days
Hemoglobin ?  g/dL (without transfusion for at least one month)
Hemoglobin > . mg/dL (without transfusion in the preceding  days)
Hemoglobin >. g/dL (may be maintained by transfusion)
Hemoglobin >= . g/dL with no blood transfusion in the past  days.
Hemoglobin >=  g/dL (transfusion allowed)
Hemoglobin >=  g/dL (transfusion to meet this criterion is allowed)
Hemoglobin (no transfusion within prior  days) >= . g/dL
Hemoglobin >= . g/dL; if patients have a hemoglobin level below , blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= . g/dL for  days or longer
Hemoglobin >=  g/dL without transfusion in the preceding  days
Hemoglobin >=  g/dL with no blood transfusion in the past  days
Hemoglobin >  g/dl (blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= . g/dL for  days or longer)
Hemoglobin >= ; transfusion is allowed
Hemoglobin >  gm/dL without transfusion and off erythropoietin for  days or Aranesp for  days
Participants with hemoglobin level <  g/dL, within  days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
Hemoglobin <  g/dL within  days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
Hemoglobin ?. g/dL without transfusion within the  weeks prior to Day .
Hemoglobin >. g/dL (without erythropoietin or blood transfusion within the last  weeks)
Hemoglobin ?  g/dL. This criterion must be met without transfusion.
Hemoglobin >=  g/dL; erythropoietin and transfusion support is permitted provided treatments are not required more than every  weeks; hemoglobin must be stable above or equal to  g/dL for at least  weeks prior to day  of study drug without blood transfusion to maintain hemoglobin level
Hemoglobin >=  g/dL (after transfusion, if necessary) within  weeks of pre-registration
Hemoglobin >= . g/dL (may be supported by erythropoietin); AND
Patient must have a hemoglobin >=  gm/dl (this may be achieved by transfusion if needed) obtained within  days before registration; if a patient receives packed red blood cell transfusion to achieve a hemoglobin level of >=  gm/dl, the hemoglobin level needs to be stable (no drop by more than  gm/dl from the post-transfusion hemoglobin level) for at least  week
Hemoglobin >=  g/dl (can be transfusion dependent)
Hemoglobin >=  g/dL (may be post-transfusion)
Hemoglobin >= . g/dL ( g/L); previous transfusion is allowed
Hemoglobin >= . g/dL (transfusion permitted)
Hemoglobin =< . g/dL for males and =< . g/dL for females (transfusion allowed to achieve or maintain levels)
Hemoglobin ?  g/dL (transfusion is permitted to fulfill this criterion)
Within  days prior to initiation of protocol treatment: Hemoglobin >= . g/dL (after transfusion if required)
Hemoglobin >= . g/dL with no blood transfusion in the past  days.
Hemoglobin >  g/dL (prior transfusion permitted)
Hemoglobin >= . g/dL independent of transfusion
Hemoglobin > . g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)
Hemoglobin >=  g/dL (transfusion to this level is allowed)
Hemoglobin >=  g/dL (it is acceptable to reach this through transfusion)
Hemoglobin >=  g/dL (blood transfusion permitted to attain this value)
Hemoglobin >=  g/dl (transfusion permitted)
Has hemoglobin <.g/dL. The use of transfusion with pRBC to correct anemia and meet eligibility criteria will not be allowed.
Hemoglobin >=  g/dL (without transfusion within  days of assessment)
Hemoglobin >=  g/dL (after transfusion if necessary)
Hemoglobin >=  g/dL; if anemia is present to the extent that the hemoglobin is <  g/dL, then correction by transfusion is indicated before entry into this study
Hemoglobin ?  g/dL, (?  g/dL for subjects who are transfusion dependent)
Hemoglobin >=  mg/dL (in the absence of transfusion within  hours prior to dosing)
Hemoglobin . g/dL (transfusion to meet this criterion is permitted)
Hemoglobin ? g/dL, without the need for transfusion in the  weeks prior to screening
Hemoglobin ?  g/dL, without the need for transfusion in the  weeks prior to screening
Hemoglobin >=  g/dL (may be post-transfusion)
Hemoglobin >=  g/dL (it is acceptable to reach this through transfusion)
The hemoglobin level must be greater than  g/dL; low hemoglobin counts may be corrected with transfusion to achieve eligibility for study
Hemoglobin at least  g/L (transfusion is allowed to achieve hemoglobin of  g/L)
Hemoglobin ? . g/dL (in case of transfusion stable for ? days prior to treatment start)
Hemoglobin ? g/dL [transfusion permitted]
Hemoglobin ? g/dL [transfusion permitted]
Hemoglobin >=  g/dL; subjects may not have had a transfusion within  days of screening assessment
Hemoglobin >  g/dl (may be transfusion dependent)
Hemoglobin >= . g/dL\r\nNote: patient may receive blood transfusion to achieve a hemoglobin >= . g/dL; however, hemoglobin must be stable at or above  g/dL two weeks prior to dosing
Hemoglobin > . g/dL (no transfusion permitted within  week)
Hemoglobin >= g/dL (transfusion permitted)
Hemoglobin < g/dL (may be determined following transfusion)
Hemoglobin >=  g/dL (acceptable to reach this via transfusion)
Hemoglobin >=  g/dL (acceptable to reach this via transfusion)